The Translational Landscape Revealed the Sequential Treatment Containing ATRA plus PI3K/AKT Inhibitors as an...

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Acute myeloid leukemia (AML) remains a challenging hematologic malignancy.
• All-trans retinoic acid (ATRA) is a key therapeutic agent in AML treatment.
• Understanding ATRA's molecular mechanisms is crucial for optimizing therapy.

Purpose of the Study:

• To investigate the role of translational regulation in ATRA's efficacy against AML.
• To elucidate the signaling pathways involved in ATRA-induced AML cell differentiation.
• To explore novel combination strategies for enhanced AML treatment.

Main Methods:

• Analysis of global translation and protein synthesis in AML cells.
• Assessment of eukaryotic initiation factor 4E (eIF4E) role in ATRA response.
• Transcriptomic analysis to identify ATRA-regulated genes.
• Investigation of phosphatidylinositol-3-kinase/Akt (PI3K/AKT) signaling.
• Evaluation of sequential ATRA and PI3K/AKT inhibitor treatment in AML models.

Main Results:

• ATRA suppressed global translation and protein synthesis in AML cells.
• eIF4E downregulation was essential for ATRA-induced growth arrest and differentiation.
• ATRA-regulated genes were enriched in PI3K/AKT signaling pathways.
• Sequential treatment with ATRA and PI3K/AKT inhibitors induced apoptosis and inhibited clonality.
• This strategy suppressed FLT3-ITD-driven transformation of hematopoietic stem/progenitor cells.

Conclusions:

• ATRA's therapeutic effect in AML relies on its translational regulatory functions.
• PI3K/AKT signaling is critical for ATRA-mediated AML cell differentiation.
• A sequential treatment approach combining ATRA with PI3K/AKT inhibitors shows significant potential for AML therapy.
• Further clinical studies are warranted to validate this sequential strategy.